Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

[18 F]AV-1451 binding and postmortem pathology of CBD.

Coakeley S, Ang LC, Jansen GH, Cho SS, Lang AE, Houle S, Kalia LV, Strafella AP.

Mov Disord. 2018 Aug;33(8):1360-1361. doi: 10.1002/mds.27356. Epub 2018 Aug 23. No abstract available.

PMID:
30136331
2.

Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.

O'Hara DM, Kalia SK, Kalia LV.

Br J Pharmacol. 2018 Aug;175(15):3080-3089. doi: 10.1111/bph.14345. Epub 2018 Jun 3. Review.

PMID:
29722028
3.

Is there a role for MR-guided focused ultrasound in Parkinson's disease?

Meng Y, Voisin MR, Suppiah S, Kalia SK, Kalia LV, Hamani C, Lipsman N.

Mov Disord. 2018 Apr;33(4):575-579. doi: 10.1002/mds.27308. Epub 2018 Feb 24. No abstract available.

PMID:
29476631
4.

Complex genomic rearrangement in SPG11 due to a DNA replication-based mechanism.

Baskin B, Kalia LV, Banwell BL, Ray PN, Yoon G.

Mov Disord. 2017 Dec;32(12):1792-1794. doi: 10.1002/mds.27188. Epub 2017 Oct 30. No abstract available.

PMID:
29082553
5.

Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.

Friesen EL, De Snoo ML, Rajendran L, Kalia LV, Kalia SK.

Parkinsons Dis. 2017;2017:5015307. doi: 10.1155/2017/5015307. Epub 2017 Aug 21. Review.

6.

UNC-18 and Tomosyn Antagonistically Control Synaptic Vesicle Priming Downstream of UNC-13 in Caenorhabditis elegans.

Park S, Bin NR, Yu B, Wong R, Sitarska E, Sugita K, Ma K, Xu J, Tien CW, Algouneh A, Turlova E, Wang S, Siriya P, Shahid W, Kalia L, Feng ZP, Monnier PP, Sun HS, Zhen M, Gao S, Rizo J, Sugita S.

J Neurosci. 2017 Sep 6;37(36):8797-8815. doi: 10.1523/JNEUROSCI.0338-17.2017. Epub 2017 Aug 8.

7.

Biomarkers for cognitive dysfunction in Parkinson's disease.

Kalia LV.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S19-S23. doi: 10.1016/j.parkreldis.2017.07.023. Epub 2017 Jul 24. Review.

PMID:
28781202
8.

Animal models of α-synucleinopathy for Parkinson disease drug development.

Koprich JB, Kalia LV, Brotchie JM.

Nat Rev Neurosci. 2017 Sep;18(9):515-529. doi: 10.1038/nrn.2017.75. Epub 2017 Jul 13. Review.

PMID:
28747776
9.

α-Synuclein and Parkinsonism: Updates and Future Perspectives.

Rosborough K, Patel N, Kalia LV.

Curr Neurol Neurosci Rep. 2017 Apr;17(4):31. doi: 10.1007/s11910-017-0737-y. Review.

PMID:
28324300
10.

Exploiting the aggregation properties of alpha-synuclein for diagnostic purposes.

Breen DP, Kalia LV.

Mov Disord. 2017 Jan;32(1):106. doi: 10.1002/mds.26884. Epub 2016 Nov 29. No abstract available.

PMID:
27896833
11.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE.

Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21. Review.

PMID:
27776749
12.

Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease.

Rowland NC, Kalia SK, Kalia LV, Larson PS, Lim DA, Bankiewicz KS.

Mol Ther Methods Clin Dev. 2016 Jan 13;3:15051. doi: 10.1038/mtm.2015.51. eCollection 2016. Review.

13.

Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD.

Kalia LV, Lang AE.

Nat Rev Neurol. 2016 Feb;12(2):65-6. doi: 10.1038/nrneurol.2015.249. Epub 2016 Jan 18. Review. No abstract available.

PMID:
26782330
14.

Disease-modifying strategies for Parkinson's disease.

Kalia LV, Kalia SK, Lang AE.

Mov Disord. 2015 Sep 15;30(11):1442-50. doi: 10.1002/mds.26354. Epub 2015 Jul 24. Review.

PMID:
26208210
15.

α-Synuclein and Lewy pathology in Parkinson's disease.

Kalia LV, Kalia SK.

Curr Opin Neurol. 2015 Aug;28(4):375-81. doi: 10.1097/WCO.0000000000000215. Review.

PMID:
26110807
16.

Parkinson's disease.

Kalia LV, Lang AE.

Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3. Epub 2015 Apr 19. Review.

PMID:
25904081
17.

Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.

Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C.

JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704.

18.

Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.

Beilina A, Rudenko IN, Kaganovich A, Civiero L, Chau H, Kalia SK, Kalia LV, Lobbestael E, Chia R, Ndukwe K, Ding J, Nalls MA; International Parkinson’s Disease Genomics Consortium; North American Brain Expression Consortium, Olszewski M, Hauser DN, Kumaran R, Lozano AM, Baekelandt V, Greene LE, Taymans JM, Greggio E, Cookson MR.

Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2626-31. doi: 10.1073/pnas.1318306111. Epub 2014 Feb 7.

19.

Direct detection of alpha synuclein oligomers in vivo.

Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, McFarland NR, Fan Z, Hyman BT, McLean PJ.

Acta Neuropathol Commun. 2013 May 9;1:6. doi: 10.1186/2051-5960-1-6.

20.

Author response.

Kalia LV, Lang AE, Aviv RI, Masellis M.

Neurology. 2013 Sep 24;81(13):1181. No abstract available.

PMID:
24191352

Supplemental Content

Loading ...
Support Center